ProQR Therapeutics (NASDAQ:PRQR) Receives $3.72 Consensus PT from Analysts

ProQR Therapeutics (NASDAQ:PRQRGet Free Report) has received a consensus rating of “Buy” from the five analysts that are covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have issued a report on the stock in the last year is $3.72.

PRQR has been the subject of several recent research reports. StockNews.com downgraded ProQR Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Chardan Capital upgraded shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $2.00 target price for the company in a report on Wednesday, November 8th. Finally, Raymond James reduced their target price on shares of ProQR Therapeutics from $5.00 to $4.00 and set an “outperform” rating for the company in a report on Wednesday, November 8th.

View Our Latest Analysis on ProQR Therapeutics

Institutional Investors Weigh In On ProQR Therapeutics

Large investors have recently bought and sold shares of the company. Belvedere Trading LLC purchased a new stake in ProQR Therapeutics in the 4th quarter worth approximately $42,000. Tower Research Capital LLC TRC boosted its position in ProQR Therapeutics by 164.8% in the 1st quarter. Tower Research Capital LLC TRC now owns 14,132 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 8,796 shares in the last quarter. BNP Paribas Financial Markets boosted its position in ProQR Therapeutics by 137.3% in the 4th quarter. BNP Paribas Financial Markets now owns 15,901 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 9,200 shares in the last quarter. Mariner LLC purchased a new stake in ProQR Therapeutics in the 4th quarter worth approximately $68,000. Finally, Two Sigma Securities LLC purchased a new stake in ProQR Therapeutics in the 1st quarter worth approximately $41,000. Hedge funds and other institutional investors own 26.15% of the company’s stock.

ProQR Therapeutics Stock Up 4.8 %

Shares of PRQR opened at $2.20 on Thursday. The firm has a market capitalization of $177.80 million, a P/E ratio of -4.68 and a beta of 0.20. ProQR Therapeutics has a 12-month low of $1.11 and a 12-month high of $3.85. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 0.06. The firm has a fifty day moving average price of $2.08 and a 200-day moving average price of $1.66.

About ProQR Therapeutics

(Get Free Report

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

See Also

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.